Profiel
Pablo Umaña is the founder of Roche Glycart AG, which was founded in 2000.
He held the title of Research Director at the time of founding.
Additionally, he worked as Head-Cancer Immunotherapy Discovery at Roche Holding AG in a former position.
Actieve functies van Pablo Umaña
| Bedrijven | Functie | Begin |
|---|---|---|
Roche Glycart AG
 Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Founder | 01-09-2000 |
Eerdere bekende functies van Pablo Umaña
| Bedrijven | Functie | Einde |
|---|---|---|
| ROCHE HOLDING AG | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ROCHE HOLDING AG | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Roche Glycart AG
Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Health Technology |
